CD34 and acute myeloid leukemia: However, in December 2014, orphan designation (EU/3/14/1395) was granted by the European Commission to Glycostem, for the GCT-NK cell product, made of allogeneic ex vivo-generated natural killer (NK) cells from CD34+ CB progenitor cells for the treatment of acute myeloid leukemia (EMA/COMP/730059/2014 Committee for Orphan Medicinal Products).